Article
Microvascular decompression for trigeminal neuralgia: preliminary results and an open invitation to join a european multicenter retrospective study
Search Medline for
Authors
Published: | June 9, 2017 |
---|
Outline
Text
Objectives: Treatment of all patients with classic trigeminal neuralgia (TN) begins with drug therapy. The gold standard remains carbamazepine. However, the efficacy of carbamazepine is compromised by its adverse effects. Furthermore, after long-term follow-up (5 – 16 years) only 22% of participants still find carbamazepine effective. Aim of this study is to assess the clinical outcome following the surgical treatment of TN and find potential factors for treatment failure.
Methods: A multicenter retrospective data analysis will be performed. The following factors will be analyzed as possible risk factors for treatment failure: 1) Duration of symptoms 2) Low/high volume centers 3) Technique: Neurovascular interposition or neurovascular transposition 4) Number of affected nerve branches 5) Presence or absence of neurovascular conflict on MRI 6) Indication for surgery: medical treatment failure (persisting pain) or intolerable adverse effects of the medication. With a study power of 80%, 688 patients will be needed. Primary outcome is pain-free patients at last follow up.
Results: For now 265 patients from 4 institutions have been analysed. Follow up data was obtained form 186 (73%). 122 patients were male (47.7%); mean age was 64 years. Mean duration of symptoms until surgery was 49.53 months (4,1 years).From 155 patients with available imaging data 115 (74.2%) had a visible conflict on the MRI. 64% of patients were pain free at last follow up. Facial hyposthesia was the most common complication and was seen in 9.4% of patients. There were no mortalities.
Conclusion: Microvascular decompression for trigeminal neuralgia is a safe and effective treatment modality. More institutions are invited to join our european wide effort.